Memory Disorders Clinical Trials

Active, recruiting:

Sponsor: Eisai and Biogen (Clarity AD) 
Intervention: BAN2401 (Monoclonal antibody binding to amyloid)
Indication: MCI
Clinicaltrials.gov identifier: NCT03887455
PI: Sharon Sha, MD
Contact: Viktoriya Bourakova, viktoriya.bourakova@stanford.edu
Inclusion criteria:
·       MMSE score >=22 at Screening
·       CDR (global) 0.5 or 1
·       Age 50-90
·       Stable AD meds for > 3 months

Active, not recruiting:

Sponsor: Genentech (Lauriet Study)
Intervention: RO7105705 (Monoclonal antibody binding to tau)
Indication: Moderate AD
Clinicaltrials.gov identifier: NCT03828747
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Biogen (Tango Study)
Intervention: BIIB092 (Monoclonal antibody binding to tau)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT03352557
PI: Sharon Sha, MD
Contact: Viktoriya Bourakova, viktoriya.bourakova@stanford.edu

Sponsor: Genentech (Tauriel Study)
Intervention: RO7105705 (Monoclonal antibody binding to tau)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT03289143
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Alzheimer's Disease Cooperative Study (PeaceAD Study)
Intervention: Prazosin
Indication: Probable or possible AD and disruptive agitation
Clinicaltrials.gov identifier: NCT03710642
PI: Victor Henderson, MD and Sharon Sha, MD
Contact: Amanda Ng, amandang@stanford.edu

Sponsor: Cortexyme (Gain Study) 
Intervention: COR388 (Gingipain inhibitor) 
Indication: Mild to Moderate AD
Clinicaltrials.gov identifier: NCT03823404
PI: Sharon Sha, MD
Contact: Amanda Ng, amandang@stanford.edu

Completing, not recruiting:

Sponsor: Novartis (Generations II Study)
Intervention: CNP520 (Active BACE-1 Inhibitor)
Target Population: Cognitively Unimpaired APOE₄ Homozygotes or Amyloid Positive Heterozygotes
Clinicaltrials.gov identifier: NCT03131453
PI: Sharon Sha, MD
Contact: Amanda Ng, amandang@stanford.edu

Sponsor: Novartis (Generations I Study)
Intervention: CAD106 (Induces Active Antibody without activating Aβ-reactive T cells) and CNP520 (BACE-1 Inhibitor)
Target Population: Cognitively Unimpaired APOE₄ Homozygotes
Clinicaltrials.gov identifier: NCT02565511
PI: Sharon Sha, MD
Contact: Amanda Ng, amandang@stanford.edu

Upcoming: (Recruiting by invitation only: participants who were previously enrolled in aducanumab trials) 

Sponsor: Biogen (Embark Study)
Intervention: Aducanumab (Monoclonal antibody binding to amyloid)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT04241068
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, jenn.gaudioso@stanford.edu